Amyloidosis — Trials · CancerIndex

Clinical trials

Registered studies

47 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 6
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 33%
Top sponsor: Alexion Pharmaceuticals, Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04984330	Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease(STARR)	withdrawn	Early Phase 1	0	Weill Medical College of Cornell UniversityOTHER	1	Nov 17, 2022	clinicaltrials

Data updated 22 days agoSource updated Nov 17, 2022source: clinicaltrials